A Phase 1, Open-Label, Dose-escalation and Dose-Expansion Study Evaluating AO-252, a Protein-Protein Interaction Inhibitor of TACC3, in Patients With Advanced Solid Tumors With or Without Brain Metastases

This study is testing a new experimental drug called AO-252 to see if it is safe and effective for people with advanced solid tumors, including those that have spread to the brain. Its main goal is to find the right dose of the medication for patients who have not responded well to previous cancer treatments.

This trial is for adults (18+) with advanced solid tumors or prostate cancer that has progressed after prior treatment. Eligibility depends on specific medical conditions and your cancer's genetic profile, so the study team will review your health history to see if you are a good fit.

Participants will receive the experimental drug AO-252 while the medical team closely monitors them for safety and effectiveness. Because this is a dose-finding study, you will have regular check-ups to track how you feel and how your body reacts to the medication.

The study is currently recruiting volunteers at medical centers in Detroit, Michigan; Oklahoma City, Oklahoma; and Charleston, South Carolina. If you are interested, a clinical team at one of these locations can help determine if you qualify.